Correspondence 0001193125-26-131936 from SUTRO BIOPHARMA, INC. (STRO)
SUTRO BIOPHARMA, INC.
Date: March 30, 2026 · CIK: 0001382101 · Accession: 0001193125-26-131936
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294541
Letter
Re:
SUTRO BIOPHARMA, INC. 111 Oyster Point Blvd. South San Francisco, CA 94080 March 30, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549
Attention:
Office of Life Sciences
Sutro Biopharma, Inc. Registration Statement on Form S-3 Filed March 23, 2026 File No. 333-294541 Requested Date: April 1, 2026 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: Sutro Biopharma, Inc. (the “ Registrant ”) hereby requests that the Securities and Exchange Commission (the “ Commission ”) take appropriate action to make the above-captioned Registration Statement on Form S - 3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes Amanda Rose or Ryan Mitteness, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration. The Registrant requests that it be notified of such effectiveness by a telephone call to Ms. Rose at (206) 389-4553 or, in her absence, to Mr. Mitteness at (206) 389-4533. * * *
Sincerely,
SUTRO BIOPHARMA, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP SUTRO BIOPHARMA, INC. 111 Oyster Point Blvd. South San Francisco, CA 94080 March 30, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Office of Life Sciences Re: Sutro Biopharma, Inc. Registration Statement on Form S-3 Filed March 23, 2026 File No. 333-294541 Requested Date: April 1, 2026 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: Sutro Biopharma, Inc. (the “ Registrant ”) hereby requests that the Securities and Exchange Commission (the “ Commission ”) take appropriate action to make the above-captioned Registration Statement on Form S - 3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes Amanda Rose or Ryan Mitteness, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration. The Registrant requests that it be notified of such effectiveness by a telephone call to Ms. Rose at (206) 389-4553 or, in her absence, to Mr. Mitteness at (206) 389-4533. * * * Sincerely, SUTRO BIOPHARMA, INC. By: /s/ Gregory Chow Gregory Chow Chief Financial Officer cc: Jane Chung, Chief Executive Officer Sutro Biopharma, Inc. Amanda Rose, Esq. Ryan Mitteness, Esq. Fenwick & West LLP [Signature Page to Company Acceleration Request Letter]